This is a clinical study to evaluate the bioequivalence of dasatinib tablet produced by Chia
Tai Tianqing Pharmaceutical Group Co., Ltd. and Sprycel® produced by Bristol Myers Squibb
after single dose in healthy subjects, so as to provide reference for clinical evaluation and
clinical medication; to observe the safety of the dasatinib tablet and the reference drug
Sprycel® in healthy subjects under fasting and fed states.